Upcycling discarded cellulosic surgical masks into catalytically active freestanding materials

[EN] The COVID-19 pandemic outbreak has resulted in the massive fabrication of disposable surgical masks. As the accumulation of discarded face masks represents a booming threat to the environment, here we propose a solution to reuse and upcycle surgical masks according to one of the cornerstones of the circular economy. Specifically, the non-woven cellulosic layer of the masks is used as an environmentally sustainable and highly porous solid support for the controlled deposition of catalytically active metal-oxide nanoparticles. The native cellulosic fibers from the surgical masks are decorated by titanium dioxide (TiO2), iron oxide (FexOy), and cobalt oxide (CoOx) nanoparticles following a simple and scalable approach. The abundant surface -OH groups of cellulose enable the controlled deposition of metal-oxide nanoparticles that are photocatalytically active or shown enzyme-mimetic activities. Importantly, the hydrophilic highly porous character of the cellulosic non-woven offers higher accessibility of the pollutant to the catalytically active surfaces and high retention in its interior. As a result, good catalytic activities with long-term stability and reusability are achieved. Additionally, developed free-standing hybrids avoid undesired media contamination effects originating from the release of nanoscale particles. The upcycling of discarded cellulosic materials, such as the ones of masks, into high-added-value catalytic materials, results an efficient approach to lessen the waste's hazards of plastics while enhancing their functionality. Interestingly, this procedure can be extended to the upcycling of other systems (cellulosic or not), opening the path to greener manufacturing approaches of catalytic materials.Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature

Manipulating chemistry through nanoparticle morphology

We demonstrate that the protonation chemistry of molecules adsorbed at nanometer distances from the surface of anisotropic gold nanoparticles can be manipulated through the effect of surface morphology on the local proton density of an organic coating. Direct evidence of this remarkable effect was obtained by monitoring surface-enhanced Raman scattering (SERS) from mercaptobenzoic acid and 4-aminobenzenethiol molecules adsorbed on gold nanostars. By smoothing the initially sharp nanostar tips through a mild thermal treatment, changes were induced on protonation of the molecules, which can be observed through changes in the measured SERS spectra. These results shed light on the local chemical environment near anisotropic colloidal nanoparticles and open an alternative avenue to actively control chemistry through surface morphology.LL and LML-M acknowledge funding from European Commission Grant (EUSMI 731019). Funding is also acknowledged from the Spanish MINECO (MAT2017-86659-R and MDM-2017-0720 to LML-M; MAT2017-88492-R and SEV2015-0522 to JGA) and the European Research Council (Advanced Grant 787510 4DBIOSERS to LML-M; Advanced Grant 789104-eNANO to JGA)

Multicomponent magnetic nanoparticle engineering: the role of structure-property relationship in advanced applications

Combining magnetic nanomaterials with materials of other classes can produce multicomponent nanoparticles with an entire ensemble of new structures and unique, enhanced, synergetic, and/or complementary functionalities. Here we discuss the most recent developments in the synthesis of multicomponent magnetic nanoparticles, describe the resulting structures and their novel properties, and explore their application in a variety of fields, including multimodal imaging, nanomedicine, sensing, surface-enhanced Raman scattering, and heterogeneous catalysis. The current synthetic methods (usu-ally bottom-up approaches) of multicomponent nanoparticles can produce a number of tailored mor-phologies (core@shell, yolk-shell, core-satellite, Janus, nanochains, anisotropic, etc.), making them invaluable for applications in biology, medicine, chemistry, physics, and engineering. But like any new technology, their synthesis methods need to be optimized to be simple, scalable, and as environmentally friendly as possible before they can be widely adopted. In particular, the use of life cycle assessment (LCA) to guide future works toward environmental sustainability is highlighted. Overall, this review not only presents a critical and timely summary of the state-of-the-art of this burgeoning field in both fundamental and applied nanotechnology, but also addresses the challenges associated with under-standing the particular structure-property relationships of multicomponent magnetic nanoparticles.The authors thank funding from the Spanish State Research Agency (AEI) through the project PID2019-106099RB-C43/AEI/10.13039/501100011033 and from the Basque Government Industry and Education Department under the ELKARTEK, HAZITEK and PIBA (PIBA-2018-06) programs, respectively

Size Effect in Hybrid TiO2:Au Nanostars for Photocatalytic Water Remediation Applications

TiO2:Au-based photocatalysis represents a promising alternative to remove contaminants of emerging concern (CECs) from wastewater under sunlight irradiation. However, spherical Au nanoparticles, generally used to sensitize TiO2, still limit the photocatalytic spectral band to the 520 nm region, neglecting a high part of sun radiation. Here, a ligand-free synthesis of TiO2:Au nanostars is reported, substantially expanding the light absorption spectral region. TiO2:Au nanostars with different Au component sizes and branching were generated and tested in the degradation of the antibiotic ciprofloxacin. Interestingly, nanoparticles with the smallest branching showed the highest photocatalytic degradation, 83% and 89% under UV and visible radiation, together with a threshold in photocatalytic activity in the red region. The applicability of these multicomponent nanoparticles was further explored with their incorporation into a porous matrix based on PVDF-HFP to open the way for a reusable energy cost-effective system in the photodegradation of polluted waters containing CECsThis research was funded by Spanish State Research Agency (AEI) through the project PID2019-106099RB-C43/AEI/10.13039/501100011033 and the Basque Government under the ELKARTEK program. P.M.M. thanks the FCT for contract 2020.02802.CEECIND. C.J.T. acknowledges the funding from FCT/PIDDAC through the Strategic Funds project reference UIDB/04650/2020-2023. F.Z. thanks the University of the Basque Country (UPV/EHU) for the PhD fellowship

Improved efficiency of ibuprofen by cationic carbosilane dendritic conjugates

In order to improve the efficiency of the anti-inflammatory drug ibuprofen, cationic carbosilanedendrimers and dendrons with ibuprofen at their periphery or at their focal point, respectively, havebeen synthesized and the release of the drug was studied using HPLC. Macrophages were used toevaluate the anti-inflammatory effect of the ibuprofen-conjugated dendritic systems and comparedwith mixtures of non-ibuprofen dendritic systems in the presence of the drug. The cationic ibuprofenconjugateddendron was the compound that showed higher anti-inflammatory properties. It reduces the LPS-induced COX-2 expression, decreases the release of several inflammatory cytokines such as TNFalfa, IL-1beta, IL-6 and CCL3. These results open new perspectives in the use of these compounds asdrug carriers.Ministerio de Economía y Empres

Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib

[EN] Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined use of both agents can exert a synergistic effect in the treatment of GvHD. For this purpose, we studied the effect of this combination both in vitro and in a GvHD mouse model. Our results show that ruxolitinib favors the ratio of thymic regulatory T cells to conventional T cells in culture, without affecting the suppressive capacity of these Treg. The combination of ruxolitinib with Treg showed a higher efficacy as compared to each single treatment alone in our GvHD mouse model in terms of GvHD incidence, severity and survival without hampering graft versus leukemia effect. This beneficial effect correlated with the detection in the bone marrow of recipient mice of the infused donor allogeneic Treg after the adoptive transfer.SITis study is partially funded by NovartisThe authors thank Dr. João Lacerda for critical reading of the manuscript. This work was supported by grants from Novartis and the Andalusian Regional Government (P18-RT-4047, PI-0052-2018). A.R.G. and J.A.P.S. are members of CIBERONC (CB16/12/00480) and TerCel (16/0011/0035). J.V. is member of CIBERNED (CB06/05/0027). A.R.G. is funded by a Grant of the University of Seville (US-1380874) co-funded by the European Regional Development Fund (ERDF)

La interdisciplinariedad y el itinerario curricular elegido por el estudiante, ejes fundamentales para desarrollar competencias curriculares en Química

Póster presentado en: V Jornadas de Innovación Docente de la UBU, Burgos, 21-22 de octubre de 2010, organizadas por el Instituto de Formación e Innovación Educativa-IFIE de la Universidad de Burgo

Role of age and comorbidities in mortality of patients with infective endocarditis

[Purpose]: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. [Methods]: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. [Results]: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39–1.88),and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. [Conclusion]: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio